David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Oct

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Charles Perou 2026 William L. McGuire Memorial Lecture Award

Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time

Robotic Esophagectomy Improves Lymph Node Yield in Esophageal Cancer

ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population

Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer